NCT04069572

Brief Summary

The purpose of this study is to perform a first in man study with VCR stimulation of the belly and back for patients with chronic pain conditions including pelvic pain, functional abdominal pain, or low back pain. This study will also examine VCR stimulation of the temporal region for patients with migraine with or without aura. Additional goals of the study will be to determine the safety, tolerability, and acceptability of VCR stimulation for the treatment of these pain conditions.

Trial Health

53
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial recruitment is currently suspended
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable chronic-pain

Timeline
15mo left

Started Sep 2026

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 23, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

August 28, 2019

Completed
7 years until next milestone

Study Start

First participant enrolled

September 1, 2026

Expected
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

April 24, 2026

Status Verified

April 1, 2026

Enrollment Period

1 year

First QC Date

August 23, 2019

Last Update Submit

April 21, 2026

Conditions

Outcome Measures

Primary Outcomes (2)

  • Treatment Responder

    Proportion of subjects in the treatment vs. placebo groups that are responders with greater than or equal to 50% reductions in average pain (in the primary pain area) comparing the average pain score from the 7-day baseline diary pre-treatment to the average scores based on 7-day diaries at the end of the primary outcome interval

    30 days

  • Change in Opioid Use

    Change in opioid use in daily oral morphine equivalents from the average 7-day baseline use to the post-treatment use in the 7 days at the end of the primary outcome interval.

    30 days

Secondary Outcomes (5)

  • Adverse Events

    60 days

  • Secondary Treatment Response After Crossover

    60 days

  • Change in monthly migraine days

    30 days

  • Treatment Engagement

    30 days

  • Treatment Initiation

    30 days

Study Arms (2)

Vibrotactile Stimulation

EXPERIMENTAL
Device: Vibrotactile Stimulation

Sham Stimulation

SHAM COMPARATOR
Device: Sham Stimulation

Interventions

Application of VCR stimulation to the belly and back of patients with pelvic pain, functional abdominal pain, or low back pain or to the temporal region for patients with migraine.

Vibrotactile Stimulation

Low-frequency sham of VCR stimulation

Sham Stimulation

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age greater than or equal to 18 years old.
  • Diagnosis of either chronic pelvic pain, functional abdominal pain, axial low back pain, or migraine with or without aura of at least 3 months duration.
  • English speaking
  • Ability and willingness to complete questionnaires and in-person assessments
  • Current average daily pain score of greater than or equal to 4 on the Numeric Rating Scale of Pain (0-10 scale)
  • For patients with migraine diagnosis they must report at least 2 headaches in the baseline headache diary in the 30 days preceding randomization.

You may not qualify if:

  • Any conditions causing inability to complete assessments (education, cognitive ability, mental status, medical status)
  • Any significant psychiatric problems, including acute confusional state (delirium), ongoing psychosis, or clinically significant depression
  • Any suicidality as assessed by answer of greater than 0 on question 9 the PHQ-9 assessing suicidal thoughts.
  • Any current illicit drug or alcohol abuse.
  • Any history of recurrent or unprovoked seizures.
  • Participation in another drug, device, or biologics trial concurrently or within the preceding 30 days.
  • Pregnancy, breast-feeding or lack of reliable contraception
  • Changes in pain medications in the previous 4 weeks
  • Implanted electrical stimulation device.
  • Skin infection over stimulation sites.
  • Any pain interventions in the preceding 6 weeks (epidural steroid injection, sympathetic block, peripheral nerve block, lumbar medial branch blocks) Any botulinum toxin injection in the previous 3 months
  • \. Frequent/chronic tension type headache

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Stanford Neuroscience Health Center

Palo Alto, California, 94304, United States

Location

MeSH Terms

Conditions

Chronic PainPelvic PainLow Back PainMigraine Disorders

Condition Hierarchy (Ancestors)

PainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsBack PainHeadache Disorders, PrimaryHeadache DisordersBrain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • Jennifer M Hah, MD

    Stanford University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

August 23, 2019

First Posted

August 28, 2019

Study Start (Estimated)

September 1, 2026

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

April 24, 2026

Record last verified: 2026-04

Data Sharing

IPD Sharing
Will not share

Locations